<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707287</url>
  </required_header>
  <id_info>
    <org_study_id>LUMHS/REC/-17</org_study_id>
    <nct_id>NCT04707287</nct_id>
  </id_info>
  <brief_title>Association of Tumour Grade and Sex Steroid Receptor as a Prognostic Index in Breast Cancer</brief_title>
  <official_title>Association of Tumour Grade and Sex Steroid Receptor as a Prognostic Index in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liaquat University of Medical &amp; Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liaquat University of Medical &amp; Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Null hypothesis: Histological grade of tumour bears no relation with the status of sex&#xD;
      hormone receptors.&#xD;
&#xD;
      Alternate hypothesis: Both the histological grade of tumour and expression of sex steroid&#xD;
      receptors are directly related to each other The investigators aim to;&#xD;
&#xD;
        1. see the relationship of sex steroid receptors with the histological grade of breast&#xD;
           cancer.&#xD;
&#xD;
        2. evaluate the efficacy of steroid receptors as a prognostic factor&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer accounts for the largest number of deaths amongst the female population&#xD;
      worldwide. It is now considered as a systemic disease even if diagnosed at an initial stage,&#xD;
      as the clinical behaviour cannot be accurately predicted. Due to this reason, it is subjected&#xD;
      to new dimensions of research every day. The aggressiveness of the cancer is directly&#xD;
      proportional to the histopathological grade at the time of diagnosis. This is true with&#xD;
      reference to the clinical stage at the time of presentation, the probability to metastasize&#xD;
      and potential to recur. The idea of steroids receptor expression by the tumour is not new,&#xD;
      and to evaluate their status prior to the induction of hormone therapy is a must.&#xD;
&#xD;
      The sex steroids, which are produced intratumorally, include estrogen, progesterone, and&#xD;
      androgens. They act on their specific receptors present on the cell surface, within the&#xD;
      cytoplasm and at the nuclear membrane. It is a measurement of these receptors that decide the&#xD;
      potential of an individual to respond to different types of hormones like estrogen receptor&#xD;
      blockers and aromatase inhibitors. Do the histological grade of tumour bears some relation&#xD;
      with the status of these receptors and can investigators predict and rely just on the&#xD;
      cellular behaviour of tumour for the purpose of prognosis is still under investigation. This&#xD;
      study is designed to see the relationship between the histopathological grade of the tumour&#xD;
      with the expression of sex steroid receptors. It will also try to evaluate whether these&#xD;
      receptors bear some prognostic value or not.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">January 15, 2021</completion_date>
  <primary_completion_date type="Actual">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Histopathology of tumour</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence of grade and type of breast cancer at the time of study will be recorded and analysed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steroid receptor status</measure>
    <time_frame>6 months</time_frame>
    <description>The concentrations of estrogen and progesterone receptor will be calculated and analysed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Age</measure>
    <time_frame>6 months</time_frame>
    <description>The age of patient will be calculated and compared to the primary outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State of menstruation</measure>
    <time_frame>6 months</time_frame>
    <description>The onset of premenopausal and postmenopausal status of patient will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage of tumour</measure>
    <time_frame>6 months</time_frame>
    <description>The status of clinical and pathological stage of the breast cancer at the time of study will be analysed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">382</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast Cancer Patients</arm_group_label>
    <description>All the patients irrespective of age, ethnicity and stage of disease will be including once the disease is confirmed after triple assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No intervention used. This is observational study</description>
    <arm_group_label>Breast Cancer Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All the patients irrespective of age, gender and stage of disease will be including once&#xD;
        the disease is confirmed after triple assessment. We shall cover the population in the&#xD;
        southern part of Pakistan.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients diagnosed with breast cancer irrespective of age, gender and clinical&#xD;
             stage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient who lost to follow up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fazila Hashmi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liaquat University of Medical and Health Sciences Jamshoro Pakistan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fazila Hashmi, FCPS</last_name>
    <phone>00923332608258</phone>
    <email>fazilahashmi@ymail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fazila Hashmi</name>
      <address>
        <city>Jāmshoro</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fazila Hashmi, FCPS</last_name>
      <phone>00923332608258</phone>
    </contact>
    <investigator>
      <last_name>Fazila Hashmi, FCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Riaz Akhtar</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaquat University of Medical and Health Sciences</name>
      <address>
        <city>Jāmshoro</city>
        <zip>76090</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fazila Hashmi, FCPS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Gadducci A, Biglia N, Sismondi P, Genazzani AR. Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol. 2005 Jun;20(6):343-60. Review.</citation>
    <PMID>16019385</PMID>
  </reference>
  <reference>
    <citation>Folkerd E, Dowsett M. Sex hormones and breast cancer risk and prognosis. Breast. 2013 Aug;22 Suppl 2:S38-43. doi: 10.1016/j.breast.2013.07.007. Review.</citation>
    <PMID>24074790</PMID>
  </reference>
  <reference>
    <citation>Gambardella A, Esposito D, Accardo G, Taddeo M, Letizia A, Tagliafierro R, Esposito K, Pasquali D. Sexual function and sex hormones in breast cancer patients. Endocrine. 2018 Jun;60(3):510-515. doi: 10.1007/s12020-017-1470-7. Epub 2017 Nov 14.</citation>
    <PMID>29138989</PMID>
  </reference>
  <reference>
    <citation>Stute P, Wildt L, Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric. 2018 Apr;21(2):111-122. doi: 10.1080/13697137.2017.1421925. Epub 2018 Jan 31.</citation>
    <PMID>29384406</PMID>
  </reference>
  <reference>
    <citation>Clendenen TV, Ge W, Koenig KL, Afanasyeva Y, Agnoli C, Brinton LA, Darvishian F, Dorgan JF, Eliassen AH, Falk RT, Hallmans G, Hankinson SE, Hoffman-Bolton J, Key TJ, Krogh V, Nichols HB, Sandler DP, Schoemaker MJ, Sluss PM, Sund M, Swerdlow AJ, Visvanathan K, Zeleniuch-Jacquotte A, Liu M. Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model. Breast Cancer Res. 2019 Mar 19;21(1):42. doi: 10.1186/s13058-019-1126-z.</citation>
    <PMID>30890167</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Liaquat University of Medical &amp; Health Sciences</investigator_affiliation>
    <investigator_full_name>Fazila Hashmi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Sex steroid receptors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>At the moment the facility is undecided about the plans to share the data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

